Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2016-11-18
Target enrollment:
Participant gender:
Summary
Study to determine the efficacy, safety and tolerability of first-line pazopanib followed by
second-line everolimus in metastatic and advanced renal cell carcinoma.
Due to changes in the RCC treatment landscape, info gained is no longer clinically relevant
to patients. Data collected is deemed sufficient to meet objective.